ArriVent's lung cancer drug fails late-stage FURVENT trial; shares halted

ArriVent BioPharma (Nasdaq: AVBP) said on Tuesday that its therapy firmonertinib did not meet the main goal of a late-stage trial, and the company’s shares were halted in premarket trading (https://www.reuters.com/business/healthcare-pharmaceuticals/arrivents-lung-cancer-treatment-fails-late-stage-trial-2026-10-06/).

The drug failed to meet the requirement for progression-free survival in previously untreated patients with a type of advanced non-small cell lung cancer, Reuters reported. In its company announcement, ArriVent said the global pivotal FURVENT Phase 3 trial (NCT05607550) evaluated firmonertinib monotherapy in first-line EGFR exon 20 insertion mutant non-small cell lung cancer, and that it did not meet its primary endpoint of progression-free survival as assessed by blinded independent central review (GlobeNewswire company release, Oct. 6, 2026).

Non-small cell lung cancer is the most common type of lung cancer, accounting for about 85 per cent of all lung cancer cases (https://www.reuters.com/business/healthcare-pharmaceuticals/arrivents-lung-cancer-treatment-fails-late-stage-trial-2026-10-06/).

The FURVENT trial was conducted jointly with partner Allist across global sites, with firmonertinib tested at once-daily doses of 160 mg and 240 mg against platinum-based chemotherapy with pemetrexed, the current first-line standard of care (GlobeNewswire company release, Oct. 6, 2026).